Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

The EpiPen Debacle: Are IP Issues to Blame?

9/9/2016

0 Comments

 
Washington, DC — Michael Rosen reports on TechPolicyDaily.com that it’s supposed to be success that has many fathers and failure an orphan, but the EpiPen debacle can trace its lineage to multiple ancestors.
 
For those living under a rock the last few weeks, the lifesaving auto-injector device, which delivers epinephrine to those whose severe allergies spark anaphylaxis and which sold for under $100 in 2009, has spiked in price to $600 as EpiPen manufacturer Mylan Pharmaceuticals finds itself controlling 94 percent of the epinephrine device market.
 
This unusual jump has unleashed fury across the political spectrum, with Hillary Clinton calling it “outrageous,” Senator Richard Blumenthal (D-CT) blasting Mylan’s “virtual monopoly.”
 
Also, Senate Judiciary Chairman Charles Grassley (R-IA) writing the company’s CEO to express his “significant concern” about the “unsafe situation.”
 
In response, Mylan has struggled to reassure the public by noting that few patients pay the full retail price for the auto-injectors and by offering rebates of up to $300 for some individuals.
 
So what’s behind this unusual jump? How did the market for epinephrine delivery break down so completely?
​Missteps from regulators and drugmakers
 
The Food and Drug Administration deserves some of the blame for the fiasco, as its lead-footed regulation has stifled the availability of alternatives to EpiPen.
 
For instance, Teva Pharmaceuticals, one of the world’s largest generic drug manufacturers, has worked for years to develop an alternative auto-injector and expects to put one on the market next year.
 
But the company’s efforts were rebuffed by the FDA early this year, which cited unspecified “major deficiencies” in Teva’s product.
 
And in 2012, the agency withheld approval of Sanofi-Aventis’s Auvi-Q until the company changed the name of the epinephrine device from “EpiCard” and “e-cue.”
 
Drugmakers also deserve some of the blame. Sanofi had to recall Auvi-Q last October after misdosing the delivery units. A product called TwinJect was also recalled back in 2010.
 
The role of IP
 
But in addition to these follies, various forms of intellectual property have played important roles in the story.
 
First, while the patents for epinephrine itself expired decades ago, and while the drug itself costs roughly ten cents per dose to produce, Mylan and its predecessors have zealously guarded the innovations behind the pen used to deliver the medicine.
 
For instance, Meridian Medical Technologies, which now licenses the EpiPen to Mylan, waged a years-long patent battle against Sanofi to keep Auvi-Q off the market, not settling the case until 2012.
 
Still, as some observers have noted, EpiPen was protected by the same patents in 2007 as it is now, and back then it sold for under $60.
 
But the trade name of the device also plays an important role. As one doctor-blogger explains, while doctors can write prescriptions for brand-name drugs and have pharmacists fill them with generics, if a doctor writes a script for EpiPen the pharmacist must provide an actual, brand-name EpiPen, since the injector itself is regulated as a medical device.
 
Thus, while not precisely a trademark issue, the powerful brand equity Mylan has built through its trade name IP may cause doctors to prescribe only the EpiPen in place of cheaper alternatives.
 
Finally, the intersection of IP and regulatory issues has contributed to Mylan’s market control.
 
For example, earlier this year San Diego-based Adamis Pharmaceuticals sought to circumvent Mylan’s patents by simply selling pre-dosed epi-filled syringes that patients could use to inject themselves.
 
But the FDA rejected Adamis’s application, requiring it to expand its patient usability study and stress-test its product more thoroughly.
 
Thus, the winds of regulatory and IP issues have gathered force and created a perfect storm that patients are now forced to weather. Here’s hoping it clears up soon.
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Health Care
    Healthcare
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608
732-729-9619